A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects
PHASE1CompletedINTERVENTIONAL
Enrollment
32
Participants
Timeline
Start Date
August 31, 2016
Primary Completion Date
December 6, 2016
Study Completion Date
January 25, 2017
Conditions
Early Alzheimer's Disease
Interventions
DRUG
E2609
Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
Trial Locations (3)
Unknown
Miami
Orlando
Minneapolis
All Listed Sponsors
lead
Eisai Inc.
INDUSTRY
NCT02859207 - A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects | Biotech Hunter | Biotech Hunter